| 裴耀华,苏荣英,王晓宇,等.丁苯酞对轻度缺血性血管性认知障碍合并睡眠障碍病人的疗效[J].安徽医药,2022,26(12):2516-2519. |
| 丁苯酞对轻度缺血性血管性认知障碍合并睡眠障碍病人的疗效 |
| Effect of butylphthalide on patients with mild ischemic vascular cognitive impairment and sleep disturbance |
| |
| DOI：10.3969/j.issn.1009-6469.2022.12.040 |
| 中文关键词: 丁苯酞 脑缺血 认知障碍 血管性认知障碍 睡眠障碍 |
| 英文关键词: Butylphthalide Brain ischemia Cognition disorders Vascular cognitive impairment (VCI) Sleep disorder |
| 基金项目:2021年度河北省医学科学研究课题计划( 20211125) |
|
| 摘要点击次数: 920 |
| 全文下载次数: 266 |
| 中文摘要: |
| 目的探讨丁苯酞对轻度缺血性血管性认知障碍( VCI)合并睡眠障碍病人的临床疗效。方法选取 2019年 1月至 2021年 1月在石家庄市人民医院神经内科门诊及住院轻度缺血性 VCI合并睡眠障碍病人 120例作为研究对象。按随机数字表法将其为对照组及治疗组各 60例。对照组采用抗血小板聚集、降脂稳定斑块等基础治疗 90 d。治疗组在对照组基础上应用丁苯酞，丁苯酞的用法为临床标准剂量，每次 0.2 g，3次/日，口服 90 d。观察并比较病人治疗前后 90 d症状、体征，简易智能精神状态检查量表( MMSE)、蒙特利尔认知评估量表( MOCA)、匹兹堡睡眠质量指数( PSQI)量表、疗效及不良反应。结果两组研究对象的性别、年龄及治疗前各组评分数据差异无统计学意义( P>0.05)具有可比性。治疗组治疗后 MMSE评分( 22.83±1.84)分、 MOCA评分(22.83±1.84)分均高于治疗前(20.27±1.85)分、(21.17±3.18(均 P<0.05)，PSQI量表评分( 8.52±3.05)分低于治疗前( 16.80±1.81)分( P<0.05)。治疗后，治疗组 MMSE评分、 组提高( P<0.05)治疗组 PSQI睡眠指数较对照组降低( P<0.05)。治疗组显效 31例，有效 13例，无效 16例，对照组显效 14例，有效 12例，无效 34两组疗效比较差异有)，MOCA评分较对照分例，统计学意义( Z=.3.58，P<0.001)。两组用药后均未出现任何不良反应。结论丁苯酞可改善轻度缺血性 VCI合并睡眠障碍病人认知功能，改善了生活质量，提高了睡眠质量。 |
| 英文摘要: |
| Objective To investigate the clinical effect of butylphthalide on patients with mild ischemic vascular cognitive impair.ment (VCI) complicated with sleep disorders.Methods From January 2019 to January 2021, 120 patients with mild ischemic VCIcomplicated with sleep disorders in the outpatient and inpatient Department of Neurology of Shijiazhuang People's Hospital were select.ed as the research objects. According to the random number table method, they were divided into the control group and the treatmentgroup, with 60 cases in each group. The control group was treated with anti-platelet aggregation and lipid-lowering to stabilize plaquefor 90 days. On the basis of the control group, the treatment group was treated with butylphthalide 0.2 g once, 3 times a day, orally for90 days. The symptoms, signs, mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MOCA), Pittsburgh SleepQuality Index (PSQI), efficacy and adverse reactions were observed and compared before and after 90 days of treatment. Results There were no significant differences in gender, age and scores before treatment between the two groups (P>0.05), which were compara.ble. The MMSE score (22.83±1.84) and MOCA score (22.83±1.84) in the treatment group after treatment were significantly higher thanthose before treatment (20.27±1.85) and (21.17±3.18) (all P<0.05). The PSQI score was (8.52±3.05) lower than that before treatment (16.80±1.81) (P<0.05). After treatment, the MMSE score and MOCA score of the treatment group were higher than those of the control group (P<0.05), and the PSQI sleep index of the treatment group was lower than that of the control group (P<0.05). In the treatmentgroup, 31 cases were effective, 13 cases were effective and 16 cases were ineffective, while in the control group, 14 cases were effective,12 cases were effective and 34 cases were ineffective. The difference in efficacy between the two groups was statistically significant (Z= .3.58, P<0.001). There were no adverse reactions in both groups.Conclusion Butylphthalide can improve cognitive function, qualityof life and sleep quality in patients with mild ischemic VCI complicated with sleep disorder. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
